Kuva icyorezo cyatangira, kwipimisha byagize uruhare runini mu kugenzura ikwirakwizwa rya SARS-CoV-2, virusi iteraCOVID-19.Ibizamini byihuse bya antigenbikorerwa murugo cyangwa mumavuriro bitanga ibisubizo muminota 15 cyangwa munsi yayo.Umuntu amaze gupimwa mbere, niko ashobora kwihutira kwivuza no kwitandukanya nabandi.Ariko iyo hagaragaye ubundi buryo bushya bwa virusi, izo variants ntizishobora gutahurwa nibi bizamini.
Ibizamini bya antigen byihuse byateguwe kugirango tumenye SARS-CoV-2 nucleocapsid proteine ​​cyangwa N-proteyine.Iyi poroteyine iboneka cyane mu bice bya virusi ndetse n'abantu banduye.Ikizamini cyihutas mubisanzwe irimo antibodi ebyiri zitandukanye zo gusuzuma zihuza ibice bitandukanye bya poroteyine N.Iyo antibody ihujwe na poroteyine ya N mu cyitegererezo, umurongo wamabara cyangwa ikindi kimenyetso kigaragara mugikoresho cyipimisha, byerekana ko wanduye.
Poroteyine N igizwe na 419 aminide acide yubaka.Buri kimwe muribi gishobora gusimburwa nindi aside amine na mutation.Itsinda ry'ubushakashatsi riyobowe na Ph.D.Philip Frank na Eric Ortlund bo muri kaminuza ya Emory bahagurukiye gukora iperereza ku kuntu iyi mpinduka imwe ya aside amine igira ingaruka ku mikorere y’ikizamini cyihuse cya antigen.Bakoresheje tekinike yiswe mutation yimbitse kugirango basuzume icyarimwe gusuzuma uburyo buri mutation iri muri proteine ​​N ya virusi igira ingaruka ku guhuza antibody yo gusuzuma.Ibisubizo byabo byatangajwe mu Kagari ku ya 15 Nzeri 2022.
Abashakashatsi bakoze isomero ryuzuye rya 8,000 N ihindagurika rya poroteyine.Izi variants zirenga 99.5% bya mutation zose zishoboka.Nyuma basuzumye uburyo buri variant yakoranye na antibodi 17 zitandukanye zo kwisuzumisha zikoreshwa mubucuruzi 11 bwihuse bwihuse bwibizamini bya antigen, harimo nibisanzweibikoresho byo mu rugo.
Itsinda ryasuzumye ihinduka rya N-protein rigira ingaruka ku kumenyekanisha antibody.Bashingiye kuri aya makuru, bakoze "guhunga mutation profil" kuri buri antibody yo gusuzuma.Uyu mwirondoro ugaragaza ihinduka ryihariye muri poroteyine N ishobora kugira ingaruka kubushobozi bwa antibody guhuza intego yayo.Isesengura ryerekanye ko antibodies zikoreshwa mubizamini byihuse byumunsi zimenya kandi zihuza ibintu byose byahise ndetse nubu bya SARS-CoV-2 yo guhangayikishwa no guhangayika.
Nubwo antibodiyite nyinshi zisuzumisha zemera akarere kamwe ka poroteyine N, abashakashatsi basanze buri antibody ifite umukono wihariye wo guhinduka.Mugihe virusi ya SARS-CoV-2 ikomeje guhinduka no kubyara ubundi buryo bushya, aya makuru arashobora gukoreshwa mugushira ahagaragara ibizamini bya antibodiyite zishobora gukenera gusuzumwa.
Ortlund yagize ati: "Kumenya neza kandi neza abantu banduye biracyari ingamba zikomeye zo kugabanya COVID-19, kandi ubushakashatsi bwacu butanga amakuru ku ihindagurika rya SARS-CoV-2 rishobora kubangamira gutahura."Ati: “Ibisubizo byavuzwe hano bidufasha kumenyera vuba iyi virusi mu gihe hagaragaye ubundi buryo bushya, bugaragaza ingaruka z’ubuvuzi ndetse n’ubuzima rusange.”
Amavu n'amavuko: Mutation Deep Scan itahura ihinduka ryimiterere muri SARS-CoV-2 nucleocapsid ukoresheje ibizamini byihuse bya antigen.Frank F., Kin MM, Rao A., Bassit L., Liu H, Bowers HB, Patel AB, Kato ML, Sullivan JA, Greenleaf M., Piantadosi A., Lam VA, Hudson VH, selire ya Ortlund EA.2022 15 Nzeri; 185 (19): 3603-3616.e13.Minisiteri y’imbere mu gihugu: 10.1016 / j.cell.2022.08.010.29 Kanama 2022 PMID: 36084631.
Inkunga: Ikigo cy’igihugu gishinzwe amashusho y’ibinyabuzima na Bioengineering NIH (NIBIB), Ikigo cy’igihugu cya Diyabete, Indwara zifata n’impyiko (NIDDK) n’ikigo cy’igihugu gishinzwe allergie n’indwara zanduza (NIAID), Ishyirahamwe ry’umutima ry’Abanyamerika.
Ubushakashatsi bwa NIH ni buri cyumweru kuvugurura ibyingenzi byubushakashatsi bwa NIH byasuzumwe ninzobere za NIH.Itangazwa n'ibiro bishinzwe itumanaho n'ibikorwa rusange by'umuyobozi w'ikigo cy'igihugu cyita ku buzima.